作者
Enrica Marchi, Helen Ma, Francesca Montanari, Ahmed Sawas, Jennifer K Lue, Changchun Deng, Kareema T Whitfield, Sandra Klein, Matthew V Matthew, Freedy J Loffredo, Luigi Scotto, Hyejung Lee, Hye A Kim, Alice T Jacobs, Aishling M Rada, Karen A Khan, Salvia Salvia, John Lister, Nora N Benanni, Mark A Francescone, Pier Luigi Zinzani, Wonseog Kim, Owen A O'Connor
发表日期
2020/8/15
期刊
Cancer Research
卷号
80
期号
16_Supplement
页码范围
CT160-CT160
出版商
The American Association for Cancer Research
简介
Our group has demonstrated that combinations of epigenetic modifiers produce potent synergy in pre-clinical models of PTCL, and has confirmed this data in early phase clinical studies. We showed that the combination of romidepsin and hypomethylating agents, decitabine or azacytidine, uniquely induces the expression of genes, including cancer testis antigens, gamma interferon and endogenous retrovirus. We are conducting a phase 1 study of pembrolizumab combined with pralatrexate alone (Arm A), with pralatrexate + decitabine (Arm B), or decitabine alone (Arm C) in patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma. In addition, we are conducting a Phase 1/2A study of durvalumab combined with oral 5-azacitidine + romidepsin (Arm A), pralatrexate + romidepsin (Arm B), romidepsin (Arm C), or oral 5-azacitidine (Arm D) in patients with PTCL. Patient characteristics are listed …
学术搜索中的文章
E Marchi, H Ma, F Montanari, A Sawas, JK Lue, C Deng… - Cancer Research, 2020